Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances

The National Institutes of Health's National Center for Advancing Translational Sciences (NCATS) Division of Preclinical Innovation is seeking Chemistry, Manufacturing, and Controls (CMC) services for drug substance development to support preclinical and IND-enabling studies. The contract encompasses a broad range of services including process development, manufacturing of drug substances and reference standards, stability testing, quality assurance, and regulatory documentation preparation. Key objectives include ensuring that drug substances meet sufficient quality and quantity standards for preclinical testing while adhering to current Good Manufacturing Practice (cGMP) standards and regulatory requirements. Contractors must demonstrate capability in preclinical pharmaceutical services, including process robustness studies, engineering lot development, formulation studies, and comprehensive testing protocols. The solicitation was posted on May 12, 2023, with a proposal due date of July 10, 2023, and included four amendments issued through June 29, 2023 to clarify requirements and technical specifications.

This procurement contains no set-aside designations and is open to all qualified contractors in the Medicinal and Botanical Manufacturing sector (NAICS 325411). The contract will support multiple NCATS activities ranging in size, complexity, and duration, with performance to be conducted within the United States. The solicitation included comprehensive attachments outlining sample task orders across multiple technical areas, detailed cost proposal instructions, supplier qualification questionnaires, quality agreement templates, and representations and certifications requirements. Interested contractors were required to submit proposals in accordance with the Statement of Work and provide comprehensive technical and business proposals detailing their CMC capabilities, quality systems, and cost structures. The evaluation emphasized technical expertise, manufacturing capability, quality management systems, and cost competitiveness in supporting the government's drug development initiatives.